US Stock MarketDetailed Quotes

NTHI NeOnc Technologies

Watchlist
  • 0.000
  • 0.0000.00%
Close Dec 20 09:30 ET
0Market Cap0.00P/E (TTM)

About NeOnc Technologies Company

NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration (“FDA”).

Company Profile

SymbolNTHI
Company NameNeOnc Technologies
CEODr. Thomas Chen, M.D.,PhD
MarketNASDAQ
Employees3
Fiscal Year Ends12-31

Company Executives

  • Name
  • Position
  • Salary
  • Dr. Thomas Chen, M.D.,PhD
  • Co-Chairman of the Board and Chief Executive Officer
  • 194.33K
  • Patrick Walters
  • Chief Operating Officer
  • 178.75K
  • Keithly Garnett
  • Chief Financial Officer and Director
  • 164.08K
  • Amir Heshmatpour
  • Co-Executive Chairman of the Board and Secretary
  • --
  • Bader Almonawer
  • Independent Director
  • --
  • Dr. Victoria Medvec
  • Independent Director
  • --
  • Dr. Sikirat Iyabo Tinubu-Karch, M.D.
  • Independent Director
  • --
  • Richard D. Nanula
  • Independent Director
  • --
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries

Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.